Xeris Biopharma
XERS
Xeris Biopharma (XERS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.18
- EPS estimate
- $0.01
- EPS surprise
- −1587.60%
- Revenue surprise
- +0.98%
- Revenue
- $91.0M
- Revenue estimate
- $90.1M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $0.01 | −$0.18 | −1587.60% | $91.0M | SEC |
| Q1 2026 | May 7, 2026 | −$0.00 | $0.01 | +470.37% | $82.5M | SEC |
| Q4 2025 | Mar 2, 2026 | $0.03 | $0.06 | +116.61% | $85.8M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.01 | $0.00 | −100.00% | $74.1M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.03 | −$0.01 | +64.29% | $71.5M | SEC |
| Q1 2025 | May 8, 2025 | −$0.05 | −$0.06 | −21.21% | $57.8M | SEC |
| Q4 2024 | Mar 6, 2025 | −$0.06 | −$0.03 | +46.24% | $57.0M | SEC |
| Q3 2024 | Nov 8, 2024 | −$0.09 | −$0.11 | −26.87% | $52.9M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.10 | −$0.10 | −3.09% | $46.5M | SEC |
| Q1 2024 | May 9, 2024 | −$0.11 | −$0.14 | −32.08% | $40.3M | SEC |
| Q4 2023 | Mar 6, 2024 | −$0.09 | −$0.10 | −16.96% | $42.5M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.10 | −$0.09 | +13.96% | $48.3M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.12 | −$0.14 | −21.74% | $36.9M | SEC |
| Q1 2023 | May 9, 2023 | −$0.16 | −$0.12 | +23.81% | $32.3M | SEC |
| Q4 2022 | Mar 8, 2023 | −$0.15 | −$0.10 | +32.75% | $32.5M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.15 | −$0.16 | −3.43% | $29.6M | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.22 | −$0.19 | +12.32% | $25.3M | SEC |
| Q1 2022 | May 11, 2022 | −$0.24 | −$0.25 | −2.75% | $21.9M | SEC |
| Q4 2021 | Mar 10, 2022 | −$0.21 | −$0.42 | −100.00% | $21.4M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.34 | −$0.39 | −13.87% | $11.0M | SEC |
Quarterly revenue
Frequently asked questions
When did Xeris Biopharma (XERS) last report earnings?
Xeris Biopharma last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did XERS beat earnings estimates?
No. Xeris Biopharma reported EPS of −$0.18 for Q2 2026 against a $0.01 estimate — a 1587.60% miss.
How much revenue did XERS report last quarter?
Xeris Biopharma reported $91.0M in revenue for Q2 2026, against a consensus estimate of $90.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.